Whatsapp /+1(916-304-5082)- Buy MST CONTINUS,5 mg, 10 mg, 15 mg, 30 mg, 60 mg, 100 mg, 200 mg prolonged release tablets.
CONTACT
TEL-+1(518-387-9661)
EMAIL
-manalon@protonmail.com
Whatsapp -+1(518-387-9661)
Wickr -teether
1. Name of the medicinal product
MST CONTINUS,5 mg, 10 mg, 15 mg, 30 mg, 60 mg, 100 mg, 200 mg prolonged release tablets.
2. Qualitative and quantitative composition
Each tablet contains Morphine Sulfate 5 mg, 10 mg, 15 mg, 30 mg, 60 mg, 100 mg, 200 mg.
Excipients with known effect:
5 mg tablet also contains lactose anhydrous 95 mg.
10 mg tablet also contains lactose anhydrous 90 mg.
15 mg tablet also contains lactose anhydrous 85 mg.
30 mg tablet also contains lactose anhydrous 70 mg.
60 mg tablet also contains lactose anhydrous 40 mg.
30 mg and 60 mg tablets also contain a small amount (<1 mg) sunset yellow (E110).
For the full list of excipients see section 6.1.
3. Pharmaceutical form
Prolonged-release tablet.
Film coated, biconvex tablet marked with the NAPP logo on one side and the strength of the tablet on the other.
MST CONTINUS tablets 5 mg are white
MST CONTINUS tablets 10 mg are golden brown.
MST CONTINUS tablets 15 mg are green.
MST CONTINUS tablets 30 mg are purple.
MST CONTINUS tablets 60 mg are orange.
MST CONTINUS tablets 100 mg are grey.
MST CONTINUS tablets 200 mg are teal green.
4. Clinical particulars
4.1 Therapeutic indications
For the prolonged relief of severe and intractable pain, and for the relief of post-operative pain.
4.2 Posology and method of administration
Posology
MST CONTINUS tablets should be used at 12-hourly intervals. The dosage is dependent upon the severity of the pain, the patient's age and previous history of analgesic requirements.
Prior to starting treatment with opioids, a discussion should be held with patients to put in place a strategy for ending treatment with morphine in order to minimise the risk of addiction and drug withdrawal syndrome (see section 4.4).
Adults:
A patient presenting with severe pain, uncontrolled by weaker opioids (e.g. dihydrocodeine) should normally be started on 30 mg 12 hourly. Patients previously on normal release oral morphine should be given the same total daily dose as MST CONTINUS
tablets but in divided doses at 12-hourly intervals.
Increasing severity of pain will require an increased dosage of the tablets. Higher doses should be made, where possible in 30-50% increments as required. The correct dosage for any individual patient is that which is sufficient to control pain with no,
or tolerable, side effects for a full 12 hours. It is recommended that the 200 mg strength is reserved for patients who have already been titrated to a stable analgesic dose using lower strengths of morphine or other opioid preparations.
Patients receiving MST CONTINUS tablets in place of parenteral morphine should be given a sufficiently increased dosage to compensate for any reduction in analgesic effects associated with oral administration. Usually such increased requirement is of the
order of 100%. In such patients, individual dose adjustments are required. Paediatric population:
For children with severe cancer pain, a starting dose in the range of 0.2 to 0.8 mg morphine per kg bodyweight 12 hourly is recommended. Doses should then be titrated as for adults.
Post-operative pain:
MST CONTINUS tablets are not recommended in the first 24 hours post-operatively or until normal bowel function has returned; thereafter it is suggested that the following dosage schedule be observed at the physician's discretion:
(a) MST CONTINUS tablets 20 mg 12 hourly to patients under 70 kg
(b) MST CONTINUS tablets 30 mg 12 hourly to patients over 70 kg
(c) Elderly - a reduction in dosage may be advisable in the elderly
(d) Children - not recommended
Supplemental parenteral morphine may be given if required but with careful attention to the total dosages of morphine, and bearing in mind the prolonged effects of morphine in this prolonged release formulation.
Method of administration
Route of administration: oral
MST CONTINUS tablets should be swallowed whole and not broken, chewed or crushed. The administration of broken, chewed or crushed tablets may lead to a rapid release and absorption of a potentially fatal dose of morphine (see section 4.9, Overdose).
Discontinuation of therapy
An abstinence syndrome may be precipitated if opioid administration is suddenly discontinued. Therefore, the dose should be gradually reduced prior to discontinuation.
4.3 Contraindications
MST CONTINUS tablets are contraindicated in patients with:
• Hypersensitivity to the active substance or to any of the constituents listed in section 6.1.
• severe chronic obstructive pulmonary disease
• severe bronchial asthma
• severe respiratory depression with hypoxia and/or hypercapnia
• paralytic ileus
• acute abdomen
• head injury
• delayed gastric emptying
• known morphine sensitivity
• acute hepatic disease
• concurrent administration of monoamine oxidase inhibitors or within two weeks of discontinuation of their use
Children under one year of age.
Not recommended for pre-operative use or for the first 24 hours post-operatively.
--- SoupGate-Win32 v1.05
* Origin: fsxNet Usenet Gateway (21:1/5)